OIG: Medicaid Paid $6.2B for Unapproved Drugs
OIG recommended that the FDA conduct frequent reviews of the NDC Directory to ensure its accuracy and thoroughness, and work with the Centers for Medicare & Medicaid Services and Congress to create legislative or regulatory changes that force drug makers to list all approved products with FDA before they're eligible for Medicaid payments.
In its formal response to the audit, FDA said it generally agreed with the OIG's recommendations, and had already begun implementing several initiatives to evaluate and enhance the quality of drug listing data.
CMS Paid $112M for Potentially Harmful Drugs, OIG Says
OIG: Medicare Contractor Overpaid $39.2 Million for Diabetic's Supplies
OIG: Feds Paid $43.3 Million for Possibly Ineffective Drugs
OIG: Medicare Paid $1.2 Billion For Drugs With Invalid Prescriber Numbers
John Commins is a senior editor with HealthLeaders Media.
- CFO Exchange: Smartphones Poised to Disrupt Healthcare, Says Topol
- CNO on Hospital Redesign: 'You Can't Over-Communicate'
- How Digital Strategy Shapes Patient Engagement at Boston Children's Hospital
- Consumerism Drives Healthcare Branding, Rebranding Efforts
- PA Ranks See 'Phenomenal Growth,' Lack of Diversity
- Half of All Primary Care, Internal Medicine Jobs Unfilled in 2013
- 3 Traits Personality Assessments Can't Reveal
- Carondelet to Pay $35M to Settle Fraud Allegations
- Antibiotic Overuse a 'Huge Threat' to Patient Safety, Says CDC
- Cleveland Clinic Partners with North Shore-LIJ for Heart Care